tbuckley/cabot-search huggingface dataset:
Abstract 2616: The Prognostic Value Of The Wnt Antagonist Dickkopf-1 (dkk-1) In Patients Presenting With An Acute Coronary Syndrome
Authors: Michael W Weber, A Aicher, S Fichtlscherer, T Trepels, B Dippel, Holger Moellmann, Albrecht Elsaesser, Stefanie Dimmeler, Christian Hamm, Andreas Zeiher
Journal: Circulation (2007)

Background  The Wnt signalling pathway is an important regulator of adult tissue maintenance and homeostasis. Disorders in Wnt signaling cause human degenerative diseases as well as cancer. Dickkopf-1 (DKK-1) is negative regulator protein of the Wnt pathway and is associated with a variety of organic diseases. Under the hypothesis that DKK-1 as a regulator protein is involved in ventricular remodelling after myocardial infarction we aimed to investigate the prognostic value of serum measurement of DKK-1 in patients with acute coronary syndromes.   Methods and results  From April 2003 until April 2005 1136 consecutive patients (age 64±12 years; 347 females) with an ACS within the last 48 hours, who were referred for early invasive diagnositc were included. Follow up data were available for 1128 (99.3%) patients. Serum samples on admission were available for 1092 (97%) patients and from 820 (72%) patients a second sample the day following admission. Values are expressed as median. Values of DKK-1 on admission and at the day following admission were elevated. There was no difference between patients with ST-elevation myocardial infarction (STEMI) and Non ST-elevation ACS (6.71 vs. 6.70 pg/ml; p=0.97 on admission and 5.35 vs. 5.57 pg/ml; p=0.32 and the day following admission). During follow up 77 (6.8%) patients deceased. Survivors had significant lower DKK-1 levels on admission (6.7 (4.4 –9.9) pg/ml vs. 7.8 (5.7–11.3) pg/ml; p= 0.02) and at the day following admission (5.5 (3.9 –7.7) pg/ml vs. 6.8 (4.9 –9.8) pg/ml; p=0,007) as compared to those patients who died. Elevated DKK-1 levels above an optimised cut-off value were related to an increased mortality rate (8.3% vs. 4.2%; p=0.015 for DKK-1 values on admission and 8.6% vs. 4.1%; p=0.018 for DKK-1 values at the day following admission). Similar findings were obtained by Kaplan-Meier analysis (Log Rank 6.07, p=0.014 for DKK-1 values on admission and Log Rank 6.65, p=0.01 for DKK-1 values at the day following admission).   Conlcusions  Elevated serum levels of Dickkopf-1 (DKK-1), a major antagonist of the Wnt signalling pathway, are associated to an increased mortality rate in patients with an acute coronary syndrome and provide prognostic information. However, the underlying mechanisms are unknown
Abstract 13377: Optimal Timing of Invasive Angiography in NSTEMI (LIPSIA-NSTEMI Trial)
Authors: Holger Thiele, Justus Rach, Norbert Klein, Dietrich Pfeiffer, Andreas Hartmann, Rainer Hambrecht, Peter Sick, Ingo Eitel, Steffen Desch, Gerhard Schuler
Journal: Circulation (2011)

Background: The optimal timing of intervention in non-ST-elevation myocardial infarction (NSTEMI) remains uncertain. Aim of this multicenter trial was to assess whether an immediate invasive approa...
Abstract 2430: Targeted alpha-v Integrin Imaging Defines Spatial and Temporal Changes in the Angiogenic Process Post Myocardial Infarction
Authors: Zakir Sahul, Donald P Dione, Lawrence Dobrucki, Leszek Kalinowski, Matthew Brennan, Choukri Mekkaoui, Patti Cavaliere, Christi Hawley, Xiaoyue Hu, Helena Haramis, Paul M Evans, Christopher Weyman, Yi-Hwa Liu, Joseph Madri, Albert J Sinusas
Journal: Circulation (2006)
Tick-borne encephalitis in Europe, 2007 to 2009
Authors: O Donoso Mantke, C Escadafal, M Niedrig, M Pfeffer, collective on behalf of the Working group for
Journal: Eurosurveillance (2011)

As a follow-up of a retrospective survey on tick borne-encephalitis (TBE) in 2008, the European Network for Diagnostics of 'Imported' Viral Diseases launched a new survey in 2010, to collect broader information on TBE prevalence between 2007 and 2009 and to observe possible changes compared to the previous data. A two-part questionnaire was mailed to contact points in all European Union (EU) Member States and four non-EU countries (Bosnia and Herzegovina, Norway, Russia, and Switzerland). The first part was identical to the 2008 survey, requesting information on case definition, diagnostic methods, investigations regarding tick-transmitted diseases, endemic foci mapping, vaccination programmes, and recommendations for travellers. The second newly added part, inquired about geographic and seasonal distribution of TBE cases, imported cases, TBE subtypes, animal cases, and prevalence in ticks and wildlife hosts. Of 28 participat-ing countries, 16 had TBE as a notifiable disease, as in the first survey. In the 2007-2009 period, the total number of notified cases (17,818) was lower than in 2004-2006 (21,339 cases), also when subtracting Russian cases (8,207 vs 9,073 cases respectively). The highest reported incidence was 18.5 per 100,000 population in Lithuania in 2009. The 2010 study showed that increased numbers of countries used PCR and nucleotide sequencing for particular investigations. Most countries, however, relied on specific antibody detection by enzyme linked immunosorbent assay for TBE laboratory diagnosis. Disparities nevertheless remained across countries regarding case definitions, and surveillance and prevention activities. To understand changing patterns in TBE transmission, surveillance strategies including screening of vector ticks and testing of animal hosts should be harmonised and done more systematically in Europe. Collected data will support rec-ommendations concerning diagnostic and mapping methods, case reporting, vaccination programmes and information campaigns. .
Abstract 14037: Angiotensin II Promotes Atrial Fibrillation in Mice by CaMKII Oxidation
Authors: Anil Purohit, Paari Dominic Swaminathan, Biyi Chen, Niels Voigt, Olha M Koval, Elizabeth D Luczak, Zhan Gao, Na Li, Xiaoqun Guan, Beixin J He, Ramzi N El-Accaoui, Jinying Yang, William Kutschke, Madhu V Singh, Robert M Weiss, Xander H Wehrens, Long-Sheng Song, Dobromir Dobrev, Mark E Anderson
Journal: Circulation (2011)

Introduction: Atrial Fibrillation (AF) is favored by Angiotensin II (Ang II) and reactive oxygen species (ROS), but the mechanism is unknown. We hypothesized that Ang II causes oxidative activation...
Treatment goals, continuity of care, and outcome in a day hospital substance abuse rehabilitation program
Authors: J R McKay, A I Alterman, A T McLellan, E C Snider
Journal: American Journal of Psychiatry (1994)

Relationships between day hospital treatment goals, self-help group participation, and substance use outcome were examined for 180 alcohol- or cocaine-dependent male patients in a day hospital Veterans Administration substance abuse program.The primary goals assessed were completion of the day hospital program and participation in posttreatment self-help groups. For subjects who completed the day hospital program, progress toward three other goals was also assessed: decreased denial, endorsement of 12-Step beliefs, and participation in self-help groups during the day hospital program. The outcome measures were urine toxicology and self-reports of alcohol or cocaine use at 4- and 7-month post-intake follow-up interviews.Day hospital completion and participation in posttreatment self-help groups predicted better outcome. Self-help participation also predicted outcome after day hospital completion was controlled. Among subjects who completed the day hospital program, the other three goals did not predict substance use outcome. However, involvement with self-help groups during the day hospital program and decreases in denial predicted continued involvement with self-help groups.Patients who complete day hospital substance abuse rehabilitation and then continue to participate in self-help groups are likely to have lower rates of alcohol and cocaine use during follow-up. Furthermore, the beneficial effect of self-help group participation does not appear to be strictly the result of motivation or some other patient characteristic.
Abstract 4270: Comprehensive Meta-Analysis on Oral Anticoagulants for the Secondary Prevention of Coronary Artery Disease Including more than 50,000 Patients
Authors: Giuseppe Biondi Zoccai, Antonio Abbate, Marzia Lotrionte, Davide Castagno, Claudio Moretti, Filippo Sciuto, Pierluigi Omedè, Gian Paolo Trevi, Imad Sheiban
Journal: Circulation (2008)

Recurrent events remain frequent among patients with coronary artery disease (CAD). Several trials have appraised the role of oral anticoaugulants in the secondary prevention of CAD, but with inconclusive results. We thus aimed to assess the efficacy and safety of long-term oral anticoagulant treatment in patients with CAD. Potentially eligible studies were searched systematically. The primary end-point was the occurrence of death, myocardial infarction, or stroke. In addition, we appraised individual components of the primary end-point, as well as the risk of major and minor bleedings. Odds ratios (OR) with 95% confidence intervals were computed according to fixed/random effect methods. A total of 61 randomized controlled trials were retrieved, including 57,983 patients. After a median follow-up of 12 months, oral anticoagulants significantly reduced the risk of death, myocardial infarction or stroke in comparison to control therapy (OR=0.74 [0.65– 0.83], p&lt;0.001), as well as death from all causes (p&lt;0.001), myocardial infarction (p&lt;0.001), and stroke (p&lt;0.001), despite an increase in major (p&lt;0.001) and minor bleedings (p&lt;0.001). Stratification for control therapy showed that benefits were maintained when anticoagulants were compared to placebo or standard therapy without any antithrombotic medication (p0.05), despite significant increases in bleeding rates (p&lt;0.001), whereas significant benefits in terms of reduction of stroke risk occurred when comparing oral anticoagulants versus oral antiplatelet agents alone (p&lt;0.001). Specifically, an International Normalized Ratio (INR) between 2.0 and 3.0 appear critical to minimize bleeding risk and maximize antithrombotic effects. Oral anticoagulants significantly prevent adverse events in patients with established CAD in comparison to standard therapy without any antithrombotic medication. Comparisons of oral antiplatelet agents versus oral anticoagulants alone or oral anticoagulants plus oral antiplatelet agents showed conversely that oral anticoagulant therapy can achieve a favorable risk-benefit balance only in subjects without increased bleeding risk are selected and INR is maintained between 2.0 and 3.0.
Comparison of thrombospondin-1 type I repeats anti-angiogenic therapy with gemcitabine in an orthotopic pancreatic cancer model
Authors: Xuefeng Zhang, Eric Galardi, Mark Duquette, Jack Lawler, Sareh Parangi
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

3036 

Introduction: Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. We hypothesized that an anti-angiogenic domain of thrombospondin-1 (TSP-1), the three type I repeats (3TSR), can be used to reduce tumor burden of mice with orthotopic pancreatic cancer. Anti-tumor efficacy of 3TSR was compared to gemcitabine controls. Methods: An orthotopic mouse model of human pancreatic cancer was developed using intrapancreatic injection of human pancreatic cancer cells (AsPC-1). One week after tumor implantation, mice were treated with 3TSR (n=9, 3 mg/kg/day), gemcitabine (n=6, 150 mg/kg, biweekly) or the combination of the two drugs (n=11) for 3 weeks. Control mice (n=11) received equivalent volume of phosphate buffered saline. The effects of 3TSR and/or gemcitabine on tumor volume, tumor necrosis, microvessel density (CD31), pancreatic cancer cell proliferation (PCNA), apoptosis (TUNEL) and tumoral endothelial cell apoptosis (CD31T combination 10%). AsPC-1 tumors treated with 3TSR showed reductions in both blood vessel number and average area, and 3TSR significantly decreased tumor microvessel density (MVD) (3.13%, control 7.69%, p<0.05). Gemcitabine treatment resulted in a moderate decrease in MVD (5.72%, p<0.05 vs. control), and the MVD of tumors from mice treated with 3TSR plus gemcitabine was 3.76%. The apoptotic rates of tumoral endothelial cells were significantly increased after 3TSR treatment (13.43%, control 3.72%, p<0.0001), while 3TSR showed no effects on pancreatic cancer cell proliferation or apoptosis. In contrast, gemcitabine had moderate effects on tumoral endothelial cell apoptosis (7.11%), but significantly inhibited tumor cell proliferation (9.05% vs. control 19.23%, p<0.001) and induced tumor cell apoptosis (19.19% vs. control 5.27%, p<0.001). Conclusion: Anti-angiogenic therapy with 3TSR significantly reduced tumor volume and vascular density in mice with orthotopic pancreatic tumors, and may prove to be an effective novel treatment for human pancreatic cancer.
Abstract 8743: Assessment of Aortic Annulus Diameter with Three-dimensional Transesophageal Echocardiography: Implications for Transcatheter Aortic Valve Implantation
Authors: Catherine Dao, Dominik Fleischmann, Benjamin Kratzert, Jimmy K Wong, Michael V McConnell, David H Liang
Journal: Circulation (2010)

Background:  Transcatheter aortic valve implantation (TAVI) relies on imaging of the aortic annulus for device sizing. 3D transesophageal echocardiography (TEE) may provide more accurate dimensions than 2DTEE because the annulus shape is oblong rather than circular. We compared 2DTEE and 3DTEE annular measurements and hypothesized that 3DTEE could impact strategy in TAVI by influencing the decision to implant a device and prosthesis size.   Methods:  Annular diameter was measured with 2DTEE and 3DTEE in 41 consecutive patients with severe aortic stenosis who underwent TAVI. 2DTEE measurements were taken at the leaflet insertion points in the long axis view. 3DTEE diameter was calculated as the mean of minor and major axes measurements of the annulus, which was located at the base of all 3 leaflets from reconstructed orthogonal long and short axis views. Device implantation and prosthesis size were chosen based on manufacturer guidelines (Edwards Lifesciences, Irvine, CA) using perioperative 3DTEE measurements. Agreements between 2DTEE and 3DTEE measurements were assessed. Impact on TAVI strategy was determined if the 2DTEE measurement would Results in exclusion or selection of a different prosthesis size than what was chosen during the actual procedure.   Results:  3DTEE measurements of the annulus correlated well with 2DTEE (r = 0.77, p   2+) paravalvular or central aortic regurgitation.   Conclusions:  Use of 3DTEE during TAVI improves visualization of annulus shape and may have important clinical implications for device sizing. The low incidence of clinically significant postoperative valve regurgitation in our study suggests appropriate sizing was obtained using 3DTEE. 2DTEE led to larger measurements than 3DTEE and would have changed strategy in 1/3 of patients, including the exclusion of patients who successfully underwent device implantation.
Dexamethasone for the treatment of depression: a randomized, placebo- controlled, double-blind trial
Authors: G W Arana, A B Santos, M T Laraia, S McLeod-Bryant, M D Beale, L J Rames, J M Roberts, J K Dias, M Molloy
Journal: American Journal of Psychiatry (1995)

The authors' goal was to assess dexamethasone for the treatment of depression.Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test.Seven (37%) of the 19 patients given dexamethasone but only one (6%) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it.A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.
Target-based molecular pathway characteristics of cervical adenocarcinoma and squamous cell carcinoma
Authors: Yong-Wan Kim, Aery Lee, Jae Eun Shin, Seo Yun Tong, Gye Hyun Nam, Keun Ho Lee, Tae Chul Park, Woong Shick Ahn
Journal: Cancer Research (2007)

AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

4429 

Objective : Invasive cervical cancer can be divided in two major histological types: squamous cell carcinoma (SCC) and adenocarcinoma (AC). Although the incidence of SCC of the uterine cervix has been decreasing recently, that of cervical adenocarcinoma has been increasing in recent years. Although several factors have been established as important initial events for the tumorigenesis of cervical carcinoma, the reports regarding the molecular biology involved in the cellular process are rare. Therefore, there is an urgent need for molecular marker studies of AC and SCC of the uterine cervix. Materials and Methods : This study utilized oligomicroarray and pathway analyses to characterize a transcriptomic signature with molecular networks associated with AC and SCC. A 10K oligomicroarray was used to identify potential transcripts that were differentially expressed in cervical cancers from 28 patients and common reference RNAs from 17 different normal cervixes. Molecular networks were correlated using genomics tools to globally explore cellular pathways. Results : Gene expression levels, of 46 transcripts, separated cancer samples into AC and SCC groups. Genes including: KRT17, IGFBP2, CALCA and VIPR1 were differentially expressed in AC and SCC. In addition, we identified a transcriptomic signature that predicted tumor classification and progression based upon its cellular processes. The down-regulated signatures for SCC were cell death of pheochromocytoma cells ( P =0.0037), apoptosis of neurons ( P =0.009) and damage to DNA ( P =0.0038). By contrast, the up-regulated molecular signatures in AC were immunological disorder ( P =0.006), splenomegaly ( P =0.0053) and hepatic system disorder ( P =0.006). The G2/M DNA damage checkpoint regulation pathway ( P =0.05) was observed to be significantly linked to IGF1R as a new regulatory component of a putative cytoplasmic signaling cascade in SCC. By contrast, the antigen presenting canonical pathway ( P =0.038) appeared to be linked to PPARγ in AC. Conclusion : These experiments provide important new information regarding the role of the molecular network in mediating SCC and AC, possibly through two independent pathways, and contribute to provide new targets for the prevention and treatment of cervical cancer.
Abstract 656: Impact of Percutaneous Coronary Intervention on Ventricular Function in Potential Candidates for Prophylactic Implantable Defibrillators
Authors: Ravi K Ramana, Robert S Dieter, Joseph Cytron, Nishath Quader, David Homan, Kevin P Cohoon, Lowell Steen, Bruce E Lewis, Ferdinand Leya, David J Wilber
Journal: Circulation (2008)

While left ventricular ejection fraction (LVEF) may improve in some pts with ischemic cardiomyopathy (ICM) following percutaneous coronary intervention (PCI), there are limited data with respect to the frequency and clinical predictors of this finding in pts who are candidates for subsequent placement of an implantable defibrillator (ICD). We retrospectively identified 105 consecutive pts with an initial LVEF &lt;35% who underwent PCI and had follow-up echocardiographic assessment at least one mo (median 5.2 mo) later. No pt had a history of syncope or sustained ventricular arrhythmias. The indication for PCI was ST-elevation myocardial infarction (STEMI) in 17 patients (16.2%), non-ST-elevation MI (NSTEMI) in 76 pts (72.4%), and angina in 12 pts (11.4%). Mean age was 65 ± 12 yrs and 76% of pts were male. Hypertension was present in 80% of pts, diabetes in 47%, renal insufficiency in 30%, prior MI in 58%, and prior PCI in 51%. Following PCI, 85% received beta blockers, and 78% received ACEI or ARBs. These variables were distributed equally between groups. Overall, mean LVEF improved significantly at follow-up (27.8 ± 6.8% vs 38.3% ± 14.7%, p&lt;0.001). LVEF improved for all indications, though there was a trend toward greater improvement in pts with STEMI (table ). LVEF improved by &gt; 5% in 76 pts (72%). In 60 pts (57%) LVEF improved to a value &gt; 35%, including 14 pts with initial LVEF ≤ 25%. Multivariate analysis of variance with repeated measures demonstrated that the improvement in LVEF was independent of all other clinical variables (p&lt; 0.001), none of which alone or jointly predicted improvement. These results suggest that significant improvement in LVEF can be expected in a majority of pts with ICM following PCI, irrespective of clinical indication, and cannot be predicted easily from standard clinical variables. Decisions regarding prophylactic ICD implantation should be deferred until after late reassessment of LVEF in most of these pts.
Periodic Evaluation Of The Clone Size Is Mandatory In PNH: Study Of The Spanish Cohort Of The International PNH Registry
Authors: Ana Villegas, Ana Gaya, Emilio Ojeda, Ataulfo Gonzalez, Alvaro Urbano, Isabel Gomez Roncero, Maria Victoria Cuevas, Raul Cordoba, Isidro Jarque, Ramiro NuÃ±ez, Beatriz Arrizabalaga
Journal: Blood (2013)
Comparison of clonidine and lithium in the treatment of mania
Authors: A J Giannini, G A Pascarzi, R H Loiselle, W A Price, M C Giannini
Journal: American Journal of Psychiatry (1986)

The authors compared the antimanic effects of clonidine with lithium carbonate in a double-blind crossover design with 24 volunteers. Lithium was observed to be more effective than clonidine. Some patients reported experiencing hypotension (N=8) and depression (N=7) while taking clonidine.
Abstract 18006: A Simple Novel SELF-Pathway Appropriately Identify High Risk Patients When Admitted with Unexplained Syncope
Authors: Emad F Aziz, Chaithanya K Pamidimukala, Balaji Pratap, Joseph H Bastawrose, Terrence Park, Steven Lee, Fahad Javed, Eyal Herzog
Journal: Circulation (2011)

Background: We developed a novel SELF pathway to guide physicians in risk stratification of patients with unexplained syncope. According to our pathway patients are risk stratified twice using the acronyms SELF-A (Short period, Early-rapid onset, Loss of consciousness, Full recovery) and SELF-B (Structural heart disease, abnormal Ecg, and arrhythmia Fib/FL). We assessed the short-term outcome according to this approach. Methods: 1462 patients presented to our ED for evaluation of unexplained syncope between September 2007 and September 2009 was prospectively followed. Patients were risk assessed according to the pathway to having SELF-A and SELF-B present (Group A: SELF +/+) or not present (Group B: SELF -/-).The primary endpoint was a composite endpoint of readmission for syncope (ROS), myocardial infarction (MI), stroke or death. Follow-up was 494 ± 120 days. Results: 762 subjects were classified accordingly to the two groups. 534 (70%) patients in Group A and 228 (30%) patients in Group B. Group A were older (73 ± 15 years vs. 61 ± 21 years), with more hypertension (74% vs. 45%), diabetes (25% vs. 16%), heart failure (9% vs. 3%), and coronary disease (21% vs. 4%); p&lt;0.001. During hospital stay group A had 58 (11%) procedures including 33 device implantation, 10 EP studies, 11 tilt tables and 4 cardioversions. At 7-days follow-up group A patients had 11 (2%) events comparing to 2 (0.01%) for group B; p &lt;0.001. At 30-days follow-up group A patients had 46 (9%) events comparing to 11 (1.7%) for group B; p &lt;0.0001 as seen in Figure. Conclusions: Using a simple novel SELF pathway for patients presenting with unexplained syncope effectively identifies high risk patients who merit hospitalization for further work-up. This has important implications for the evaluation management of a common disease that poses a significant economic burden on healthcare utilization.